PPHF, Niti Aayog Co-host Global Rare Disease Conference on International Rare Disease Day ANI | Updated: Mar 05, 2021 16:43 IST
New Delhi [India], March 5 (ANI/NewsVoir): To call for effective dialogue and decisive action against the alarming challenges of rare diseases in India, People to People Health Foundation (PPHF), a public health organization working towards better healthcare and Niti Aayog, Co-hosted a Global Rare Disease Conference under the initiative Blueprint for Rare Diseases in India - Together for Rare on the International Rare Disease Day (28 February).
The virtual conference was co-powered by Takeda Pharmaceutical and was supported by Japan Embassy.
Over 7000 rare diseases have been identified globally and experts opine that only 5 per cent of these have identified treatments. The conference witnessed engaging dialogues and discussions from eminent guests who underlined the need for increasing collaboration and commitment
Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index
Wednesday, January 27, 2021 11:40AM IST (6:10AM GMT)
Company Ranked Sixth Overall and Leads the Pharmaceutical Industry in Governance of Access
Secured Industry-Leading Positions in All Three Technical Areas Evaluated
Shows Strong Performance in Health System Strengthening and Compliance
(TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021
Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated by the Index, including being ranked first in Governance of Access. Takeda also demonstrated strong performance in the areas of health system strengthening, compliance and R&D capacity building, according to the Index.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index
January 26, 2021 GMT
( TSE:4502/NYSE:TAK ) (“Takeda”) has earned an industry-leading position within the 2021
Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated by the Index, including being ranked first in Governance of Access. Takeda also demonstrated strong performance in the areas of health system strengthening, compliance and R&D capacity building, according to the Index.
ADVERTISEMENT
“This honor underscores Takeda’s commitment to prioritizing patient needs by ensuring access to our life-transforming treatments,” said Christophe Weber, Takeda president and chief executive officer. “As a purpose-driven company that puts the patient at the center of everything we do, we are committed to not just inventing